Thank you for standing by, and welcome to the Oneview Healthcare PLC annual general meeting. All participants are in a listen-only mode. There will be a presentation followed by a question-and-answer session. If you wish to ask a question, you will need to press the star key followed by the number one on your telephone keypad. I would now like to hand the conference over to Barbara Nelson, Chair. Please go ahead.
Good morning, ladies and gentlemen. My name is Barbara Nelson, and I'm very happy to welcome you as the Chair to the 2024 annual general meeting of Oneview Healthcare PLC. In accordance with the company's constitution, I have been appointed by the directors to act as Chair in respect of this AGM. Let me begin by announcing and introducing my fellow board members. With me in the boardroom is Nashina Asaria, Independent Non-Executive Director, Marc Cullen, Independent Non-Executive Director, Joe Rooney, Independent Non-Executive Director, James Fitter, Chief Executive Officer and Executive Director, Darragh Lyons, Chief Financial Officer and Executive Director, Tony Pettit, Company Secretary, as well as Charlie Carroll from A&L Goodbody and John Corrigan from KPMG.
As laid out in the notice of the meeting, we have asked people not in a position to attend the physical AGM to instead avail of the established proxy voting services in order for your vote to count, and to take the opportunity to submit in advance any questions you would like addressed at this AGM, and to avail of the teleconferencing facility to listen to the business of the meeting. The time now is just after 9:00 A.M. Dublin. Under Article 54 of the company's constitution, the quorum for this meeting is one member. As I have been appointed to be the depository nominee, ETY Limited, the company's sole registered shareholder, I can confirm that the quorum has been validly constituted and that the notice of the meeting has been provided for the requisite period and that the meeting may proceed to business.
Voting will then take place by our statutory shareholder, through me as the Chair of the meeting, in accordance with the wishes of our custodians as set out in duly completed, returned, and verified voting instruction forms received by the company in the manner outlined in the notice of this meeting. The purpose of today's meeting is to consider the resolution set out in the notice of the AGM sent to shareholders on the 7th of October 2024. But first, I hand you over to James Fitter, who would like to spend a few minutes reviewing the progress made since the last AGM and give you a business update. Following that update, I will move to shareholders in the formal business of the meeting.
Pardon me, this is the operator. We seem to have lost connection with the speaker line. Please hold while we get the line reconnected.
Good morning, everyone. Thank you all for your participation today. As you will have seen earlier this week, we were delighted to announce that we've extended our strategic partnership with Baxter International for an additional two years and expanded the agreement to include Canada. Since we began the formal sales training in November 2023, just over a year ago, our collaboration has focused on enabling Baxter to effectively deliver Oneview's innovative solutions, enhancing both patient engagement and care team efficiency. Twelve months later, we're now working on a joint product roadmap to continue to enhance the integrated experience. Since the start of the agreement, we're very proud to have successfully deployed our new digital door sign product for two Baxter customers and recently received purchase orders from an additional customer for our full suite of care experience, digital whiteboard, and digital door sign products.
Momentum in the partnership is growing, as evidenced by Baxter's internal pipeline of 139 opportunities for Oneview products. This relationship with Baxter is delivering us unparalleled access to the U.S. hospital market, and we're very excited to enter the Canadian market, which shares many characteristics with the Australian health system and represents a further 100,000 inpatient beds by way of opportunity. I also wanted to take this opportunity to address the challenging and lengthy sales and deployment cycle in the healthcare sector, particularly as it relates to your investment in Oneview. Healthcare is one of the most complex and highly regulated industries in the world. The decision-making processes within leading hospitals and health systems are meticulous by necessity. When lives are at stake, there's no room for error, and this diligence can impact and extend the sales cycle for any new technology implementation.
This extended sales cycle is indicative of the thorough vetting processes that leading institutions like NYU Langone, UCSF Health, Inova, and BJC HealthCare employ. The fact that we've already secured partnerships with such discerning organizations is a testament to the strength of our patient experience platform and its potential for widespread adoption. It also speaks to Oneview's resilience and determination. So whilst the barriers to entry in healthcare are high and require stamina, once contracted and deployed, these same barriers become defensive and protective by nature. Once a healthcare provider integrates a new platform into their system, the switching costs in terms of time, money, and operational disruption are significant. This means that while the initial sales cycle may be lengthy, the long-term relationships and revenue streams that result are robust and enduring, leading to low customer churn and extended revenue opportunities.
Moreover, the healthcare industry is on the cusp of a significant digital transformation. There's a growing recognition of the need for the virtualization of care and enhanced patient experiences. Oneview Healthcare is incredibly well positioned to lead this change. The company's success with top-tier health systems serves as a powerful endorsement that will facilitate future engagements and potentially shorten sales cycles over time. Our developing relationship with Baxter shows the potential to further shorten the sales cycle.
As a trusted provider to so many high-profile U.S. healthcare systems, they are not just providing unrivaled access to the U.S. and now the Canadian market, but by providing the gateway for their clients to purchase Oneview technologies on Baxter paper, they are reducing complexity for their customers and eliminating the need for Baxter clients to contractually onboard a new vendor, a process that we know ourselves can take six to eight months alone. As investors, it's crucial to align expectations with the realities of the market. Patience isn't just a virtue here. It's a strategic asset. The foundational work being done now is setting the stage for scalable growth and market leadership. In the world of enterprise software, especially within sectors as critical as healthcare, enduring success is seldom instantaneous. It's earned through persistence, excellence, and the unwavering belief in the value one brings to the table.
There's never been a more exciting time for bedside technology, as the most discerning healthcare systems in the United States are embracing the virtualization of care through inpatient care experience platforms. And for us, having a partner of Baxter's reputation and stature alongside us will undoubtedly accelerate this pursuit. I'd like to thank you all for your continued support. I'll pass it back to you, Barbara.
Thank you, James. So as it relates to questions, shareholders were invited to submit questions prior to the commencement of this meeting by post to the company secretary, together with evidence of their shareholding. As of 9:00 A.M. Dublin time on 28th of October 2024, the final date for receipt of questions, no questions have been received. I would remind all shareholders present that the purpose of today's meeting is specifically to consider the business of the resolutions contained in the notice, and therefore questions are limited to these matters. I will now pause to take any questions from shareholders present with us today on the resolutions before the meeting. Please address your questions to me, and if I cannot answer it, I will direct it as appropriate to one of my colleagues.
If there are any detailed supplementary questions, please direct them in writing to the Company Secretary at the company's registered office as per the investor relations section of the company's website or by email to cosec@oneviewhealthcare.com. Are there any questions from shareholders on the resolutions before the meeting today at this time?
Thank you. Once again, if you wish to ask a question, please press star one on your telephone. We'll pause a moment to allow for any questions to register. There are no questions at this time.
If there are no questions, I will now move to the formal business of the meeting. I will take the notice of the meeting issued to members on the 4th of October 2024, including the details of each of the resolutions as read. So the voting procedures. There are 15 resolutions to be considered at this AGM, full details of which are set out in the notice of the meeting. These resolutions shall be voted upon by those shareholders present today in person or by proxy. In accordance with Article 61 of the company's constitution, as Chair, I hereby demand voting on the resolutions by poll. Of the 15 resolutions being voted upon today, 14 are ordinary resolutions which, in order to be passed, must be approved by a majority of 50% plus one vote of those voting. These ordinary resolutions are identified in the notice of the meeting.
Resolution 15 is a special resolution which, in order to be passed, must be approved by a majority of not less than 75% of those voting. Every ordinary shareholder or custodian present as a nominated proxy of CDN shall have one vote for every ordinary share or custodian of which he or she is the holder. Resolutions. In accordance with the constitution, I now demand that each of the resolutions listed in the notice of the meeting is put to the meeting by way of a poll. As Chair of the meeting, I have been appointed as proxy in respect of 430,007,464 shares representing 63% of the issued capital. No other proxies have been appointed, and there are no other shareholders entitled to vote.
The proxy vote instructions delivered have been verified by Computershare by reference to the register of members, the custodian register, and a list of authenticated voting instruction forms received by the company. I now cast the votes in respect of those 430,007,464 shares in accordance with the proxy vote instructions. No further votes are to be cast, and I now declare the poll closed. I confirm that all the resolutions before the meeting have been passed by in excess of 99.7% of the votes cast. The full result of the poll, including the total of the votes cast for and against the resolutions and the abstentions, will be published immediately through the ASX on the company website tomorrow. That concludes the business of the meeting, and I would like to thank you all for your attendance today.